Bulent Ozpolat, M.D., Ph.D.

Peer-Reviewed Articles

1. Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget 8 (12) :20145-20164, 2017. PMID: 28423620.
2. Hamurcu Z, Kahraman N, Ashour A, Ozpolat B. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer. Breast Cancer Res Treat 163 (3) :485-493, 2017. e-Pub 2017. PMID: 28361350.
3. Shahbazi R, Asik E, Kahraman N, Turk M, Ozpolat B, Ulubayram K.. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine 12 (16) :1961-1973, 2017.
4. Sok SP, Arshad NM, Azmi MN, Awang K, Ozpolat B, Hasima Nagoor N.. The apoptotic effect of 1'S-1'-Acetoxychavicol Acetate (ACA) enhanced by inhibition of non-canonical autophagy in human non-small cell lung cancer cells. PLoS One 12 (2) , 2017.
5. Shahbazi R, Ozpolat B, Ulubayram K. Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond) 11 (10) :1287-308, 2016. e-Pub 2016. PMID: 27102380.
6. Gurbuz N, Asoglu M, Kahraman N and Ozpolat.. A selective Serotonin 5-HT1B receptor inhibition suppresses cell proliferation and induces apoptosis in human uterine leiomyoma cell. European Journal of Obsetrics & Gynecology and Reproductive Biology 206:114-119, 2016. e-Pub 2016. PMID: 27669395.
7. Gurbuz N, Asoglu MR, Ashour AA, Salama S, Kilic GS, Ozpolat B. A selective serotonin 5-HT1B receptor inhibition suppresses cells proliferation and induces apoptosis in human uterine leiomyoma cells. Eur J Obstet Gynecol Reprod Biol 206:114-119, 2016. PMID: 27669395.
8. Wang L, Jin Y, Qu S, Kristian A, Maelandsmo GM, Tekedereli I, Alpay N, Gorgulu K, Yuca E, Sood A, Lopez-Berestein G, Riserg B, Waehre H, Danielsen HE, Ozpolat, Saatcioglu F. STAMP2 increases oxidative stress through its ferrireductase activity and is critical for prostate cancer progression. Clinical Cancer Research, 2015.
9. Olmez I, Shen W, McDonald H, Ozpolat B. Dedifferentiation of Patient-derived glioblastoma multiforme cell lines results in a cancer stem cell like state with mitogen-independent growth. J Cell Mol Med 19 (6) :1262-72, 2015. PMID: 25787115.
10. Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clin Cancer Res 21 (9) :2127-37, 2015. e-Pub 2015. PMID: 25595279.
11. Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med 7 (3) :315-31, 2015. e-Pub 2015. PMID: 25680860.
12. Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol 47 (1) :262-8, 2015. e-Pub 2015. PMID: 25975349.
13. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun 6:7351, 2015. e-Pub 2015. PMID: 26081979.
14. Devkota AK, Warthaka M, Edupuganti R, Tavares CD, Johnson WH, Ozpolat B, Cho EJ, Dalby KN. High-Throughput Screens for eEF-2 Kinase. J Biomol Screen 19 (3) :445-52, 2014. PMID: 24078616.
15. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis 19 (1) :241-58, 2014. e-Pub 2013. PMID: 24193916.
16. Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS One 9 (8) :e105245, 2014. PMID: 25170871.
17. Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 13 (11) :2583-94, 2014. e-Pub 2014. PMID: 25193509.
18. Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med 18 (11) :2235-51, 2014. PMID: 25215932.
19. Hasima N, Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 5:e1509, 2014. e-Pub 2014. PMID: 25375374.
20. Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS One 9 (9) :e110067, 2014. e-Pub 2014. PMID: 25268648.
21. Tekedereli I, Akar U, Alpay N, Lopez-Berestein G, Sood A, Ozpolat B. Therapeutic targeting of Bcl-2 by systemically administred nanoliposomal siRNA inhibits tumor growth of ER(-) and ER(+) breast cancer xenografts by inducing authophagic and apoptotic cell death. Gene Therapy, 2013.
22. Yenigun VB, Ozpolat B, Kose GT. Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen and doxorubicin induced autophagy. Int J Mol Med 31 (6) :1477-83, 2013. e-Pub 2013. PMID: 23589132.
23. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366 (7) :610-8, 2012. PMID: 22335738.
24. Ozpolat B, Akar U, Tekedereli, Alapy N, Lopez-Berestein G. PKC Regulates Translation Initiation through PKR and elF2a in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. Leukemia Research and Treatment 2012 (2012) , 2012. e-Pub 2012. PMID: 23259068.
25. Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to Doxorubicin in an orthotopic model of breast cancer. PLoS One 7 (7) :e41171, 2012. PMID: 22911754.
26. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 18 (24) :6648-57, 2012. e-Pub 2012. PMID: 23052253.
27. Abramczyk O, Tavares CD, Devkota AK, Ryazanov AG, Turk BE, Riggs AF, Ozpolat B*, Dalby KN* (*corresponding authors). Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. Protein Expr Purif 79 (2) , 2011. e-Pub 2011. PMID: 21605678.
28. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. J Natl Cancer Inst 103 (21) :1596-612, 2011. e-Pub 2011. PMID: 21957230.
29. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9 (5) :1180-7, 2010. e-Pub 2010. PMID: 20423989.
30. Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 125 (2) :264-275, 2009. e-Pub 2009. PMID: 19408305.
31. Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein G. Death-Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia. Apoptosis 13 (7) :915-28, 2008. PMID: 18491231.
32. Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 Expression by Small Interfering RNA Induces Autophagic Cell Death in MCF-7 Breast Cancer Cells. Autophagy 4 (5) :669-79, 2008. PMID: 18424910.
33. Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy 3 (5) :480-3, 2007. e-Pub 2007. PMID: 17507797.
34. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GL. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5 (1) :95-108, 2007. PMID: 17259349.
35. Akar U, Ozpolat B (Co-First Authors), Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5 (3) :241-9, 2007. PMID: 17374730.
36. Devkota AK, Tavares CD, Warthaka M, Abramczyk O, Marshall KD, Kaoud TS, Gorgulu K, Ozpolat B*, Dalby KN* (*corresponding authors). Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase (eEF-2K) by NH125: Evidence for a Common in vitro Artifact. Biochemistry 51 (10) . e-Pub 2012. PMID: 22352903.
37. Tavares CD, O'Brien JP, Abramczyk O, Devkota AK, Shores KS, Ferguson SB, Kaoud TS, Warthaka M, Marshall KD, Keller KM, Zhang Y, Brodbelt JS, Ozpolat B*, Dalby KN* (*corresonding authors). Calcium/Calmodulin Stimulates the Autophosphorylation of Elongation Factor 2 Kinase on Thr-348 and Ser-500 to Regulate its Activity and Calcium Dependence. Biochemistry. e-Pub 2012. PMID: 22329831.
38. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B,. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6 (3) . e-Pub 2010. PMID: 20224296.
39. Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. e-Pub 2016. PMID: 28036267.
40. Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. e-Pub 2016. PMID: 27742688.
41. Hamurcu Z, Ashour A, Kahraman N, Ozpolat B.. FOXM1 regulates expression of eukaryotic elongation ftactor 2 kinase and promotes proliferation, invasion and tumorgenesis human triple negative breast cnacer cells. Oncotargt 7 (13) . e-Pub 2016. PMID: 26918606.
42. Hamurcu Z, Ashour A, Kahraman N, Ozpolat B. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. e-Pub 2016. PMID: 26918606.
43. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia . Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12 (1) :1-222. PMID: 26799652.
44. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell 28 (5) :610-22. PMID: 26481148.
45. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20 (12) :3280-8. PMID: 24756370.
46. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7 (2) :488-500. PMID: 24703838.

Invited Articles

1. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-19, 2015. e-Pub 2015. PMID: 25666164.
2. Ozpolat B, Benbrook DM. Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res 7:291-9, 2015. e-Pub 2015. PMID: 26392787.
3. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA Nanocarriers for Cancer Therapy. Adv Drug Deliv Rev 66C:110-116, 2014. e-Pub 2013. PMID: 24384374.
4. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target 21 (10) :904-13, 2013. e-Pub 2013. PMID: 24079419.
5. Klionsky DJ and 1269 others, including Bast RC, de Groot JF, Ekmekcioglu S, Fan Z, Fueyo J, Garcia-Manero G, Gomez-Manzano C, Jiang H, Lev D, Lopez-Berestein G, Lu Z, McConkey DJ, Ozpolat B, Sood AK, Younes A. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8 (4) :445-544, 2012. PMID: 22966490.
6. Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Medicine 267 (1) :44-53, 2010. PMID: 20059643.
7. Ozpolat B. Acute Promyelocytic Leukemia and Differentiation Therapy. Molecular Mechanisms of Differentiation, Retinoic Acid Resistance and Novel Treatments. Turkish Journal of Hematology 26 (2) , 2009. PMID: N/A.
8. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He YW, Heidenreich K, Hill JA, Høyer-Hansen M, Hu X, Huang WP, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska I, Moore MN, Moreira PI, Moriyasu Y, Motyl T, Münz C, Murphy LO, Naqvi NI, Neufeld TP, Nishino I, Nixon RA, Noda T, Nürnberg B, Ogawa M, Oleinick NL,Olsen LJ,Ozpolat BPaglin S, Palmer GE, Papassideri I, Parkes M, Perlmutter DH, Perry G, Piacentini M, Pinkas-Kramarski R, Prescott M, Proikas-Cezanne T, Raben N, Rami A, Reggiori F, Rohrer B, Rubinsztein DC, Ryan KM, Sadoshima J, Sakagami H, Sakai Y, Sandri M, Sasakawa C, Sass M, Schneider C, Seglen PO, Seleverstov O, Settleman J, Shacka JJ, Shapiro. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4 (2) :151-75, 2008. e-Pub 2007. PMID: 18188003.
9. Ozpolat B, Tirado-Gomez M, Lopez-Berestein G. Liposomal- All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. Current Cancer Therapy Reviews 1 (3) :239-250, 2005.
10. Ozpolat B, Lopez-Berestein G. Liposomal All-trans-Retinoic acid (ATRA) in Treatment of Acute Promyelocytic Leukemia. Leukemia and Lymphoma 45 (5) :993-941, 2002.
11. Ozpolat B, Lopez-Berestein G, Mehta K. ATRA(ouble) in Treatment of Acute Promyelocytic Leukemia. Journal of Biological Regulators and Homeostatic Agents. Journal of Biological Regulators and Homeostatic Agents 15 (2) :107-122, 2001.
12. Bircan A, Ozpolat B. EF2Kinase as novel therapeutic target in solid cancers.
13. Hasmima N, Ozpolat B. Autophagy induction by polyphenolic compounds as a potential strategy in cancer therapy. Antimicrobial Agents and Chemotherapeutics. e-Pub 2014.
14. Aslan B, Ozpolat B, Sood A, Lopez-Berestein G. Nanomedicine in Cancer. Journal Drug Targeting.
15. Hasmima N, Ozpolat B. Modulation of Autophagy by polyphenolic compounds as a Potential Therapeutic Strategy for Cancer. Cell Death & Disease 6 (5) :1509. e-Pub 2014.